To most investors, hedge funds are seen as slow, outdated financial vehicles of the past.
Keep Reading →
May 24 - News
In an already massive market segment, are dividends all you can hope for when you hunt down "elephants" like Warren Buffett does? While you probably won't get a five-bagger at...
Keep Reading →
May 22 - News
We dread some checkups. Some people even put them off. If you own Pfizer Inc. (NYSE:PFE) stock, though, there's no need for dread or delay.
Keep Reading →
May 21 - News
Investing in the stock market can sometimes be a gut wrenching experience. However, for investors in Santarus, Inc.
Keep Reading →
May 21 - News
The recession has taken a toll on economies around the world, from driving down standards of living to sending unemployment to record levels.
Keep Reading →
May 19 - News
Investors emphasize the "bio" in biotech a great deal. We look at how much patients' health improved in clinical trials.
Keep Reading →
May 16 - News
I admit to not being a big fan of many of her movies -- possibly the only man on the planet who will admit so -- but there's little denying that movie sensation Angelina Jolie...
Keep Reading →
May 16 - News
According to the Center for Disease Control and Prevention, there are only five known coronaviruses that can infect humans.
Keep Reading →
May 14 - News
Allergan, Inc. (NYSE:AGN) has been consistently increasing on the market since the market bottom, from nearly $32 per share in November 2008 to more than $116 per share in ...
Keep Reading →
May 10 - News
Take a look around the pharmaceutical industry and you won't find many companies with market caps exceeding $100 billion (seven by my count).
Keep Reading →
May 7 - News
The healthcare sector has been known for paying dependable dividends and producing strong total returns over time.
Keep Reading →
May 6 - News
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can'...
Keep Reading →
May 5 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
May 2 - News
Investing in biotech companies can be intimidating, especially for investors without a science background. But there's hope.
Keep Reading →
May 1 - News
Would you hold a pharmaceutical product presentation in Hooters? That's just one of many alleged instances that the U.S.
Keep Reading →
May 1 - News
Big pharma is a controversial industry. Along with tobacco companies, they are some of the most vilified businesses in the world.
Keep Reading →
May 1 - News
Perkins Large Cap Value Fund (JNPLX) looks for temporarily misunderstood companies.
Keep Reading →
April 30 - News
If you thought that the great run so far in 2013 was over for Biogen Idec Inc. (NASDAQ:BIIB), think again.
Keep Reading →
April 25 - News
Heart disease kills nearly 600,000 Americans every year, making it the nation's No. 1 cause of death, according to the Centers for Disease Control and Prevention.
Keep Reading →
April 24 - News
A popular drug that crosses a benchmark sale of $1 billion for the manufacturer is called a blockbuster drug.
Keep Reading →
April 18 - News
The process of developing a drug from start to finish is incredibly arduous, usually involves around $1 billion in costs, and can take upwards of a decade to complete.
Keep Reading →
April 12 - News
While the Dow Jones Industrial Average (INDEXDJX:.DJI) continues to climb to new heights on little more than a central bank-induced asset levitation scheme and closing the day...
Keep Reading →
April 12 - News
Johnson & Johnson (NYSE:JNJ) was in 67 hedge funds' portfolio at the end of December. JNJ has experienced a decrease in hedge fund interest in recent months.
Keep Reading →
April 8 - News
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Keep Reading →
April 5 - News
Over the last year the biggest drug makers, like Pfizer Inc.
Keep Reading →
April 2 - News
Last November, I examined five experimental drugs that appeared as if they had all of the tools necessary to become life-changing blockbusters from a financial and quality of ...
Keep Reading →
March 28 - News
At the moment, there are tons of gauges market participants can use to track the equity markets. A duo of the best are hedge fund and insider trading sentiment.
Keep Reading →
March 26 - News
Will good news from Europe echo on this side of the Atlantic within the next few days? Biogen Idec Inc. (NASDAQ:BIIB) is certainly hoping so.
Keep Reading →
March 25 - News
Every year, it appears that flu season starts earlier and earlier, and somehow, every year, the virus mutates into its "most virulent form ever." Sometimes it's a wonder we even...
Keep Reading →
March 25 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 22 - News
As I noted three weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
March 20 - News
Bacteria have been Public Enemy No. 1 for most of our species' time on Earth.
Keep Reading →
March 18 - News
Earnings season is winding down, with most companies already having reported their quarterly results.
Keep Reading →
March 15 - News
With interest rates still sitting near record lows, looking for current income have been forced to move away from fixed-income positions and into stocks to find yield.
Keep Reading →
March 15 - News
The market has been less than thrilled about an upcoming Supreme Court decision on the legality of the best-selling analytical test of Myriad Genetics, Inc. (NASDAQ:MYGN) .
Keep Reading →
March 5 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 5 - News
Elan Corporation, plc (ADR) (NYSE:ELN) was nice enough to give us a little more detail on what it plans to do with the $3.25 million that the biotech stands to get from Biogen...
Keep Reading →
February 25 - News
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Keep Reading →
February 22 - News
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Keep Reading →
February 20 - News
Back in 2011, generic drug giant Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) dominated the MS field, riding the coattails of its Copaxone medication to success.
Keep Reading →
February 14 - News
Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion.
Keep Reading →
February 6 - News
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons and decide whether its possible upside outweighs its risks.
Keep Reading →
February 5 - News
Despite its name, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been losing steam since the end of 2011 with revenue falling 97% in the last nine months.
Keep Reading →
February 5 - News